North America Growth Factors Market Size, Share, and Growth Forecast 2026 - 2033

The North America growth factors market size is expected to be valued at US$ 1,002.5 million in 2026 and projected to reach US$ 1,328.1 million by 2033, growing at a CAGR of 4.1% between 2026 and 2033.

Sustained growth is being driven by rising investment in biopharmaceutical research and the expanding application of growth factors in regenerative medicine and oncology therapeutics. The National Institutes of Health (NIH) has allocated substantial funding toward biomedical research in recent years, supporting growth factor-based drug discovery. Additionally, the growing prevalence of chronic diseases, including cancer and diabetes, reported by the Centers for Disease Control and Prevention (CDC), continues to fuel demand for growth factor-based diagnostics and therapeutics across the region.

Drivers - Rising Prevalence of Chronic and Age-Related Diseases

The growing burden of chronic and age-related diseases across the United States and Canada is a significant driver for the growth factors market. The Centers for Disease Control and Prevention (CDC) reports that approximately 6 in 10 American adults live with at least one chronic disease, with cancer and diabetes among the leading contributors to healthcare demand. Growth factors, including Vascular Endothelial Growth Factors (VEGFs) and Fibroblast Growth Factors (FGFs), play a critical role in oncology research, wound healing, and tissue regeneration therapies. As the American Cancer Society continues to report rising cancer incidence, particularly among aging populations, demand for growth factor-based diagnostic and therapeutic applications is expected to remain strong, reinforcing consistent market expansion across the region.

Expanding Biopharmaceutical Research and Development Investment

Robust research and development investment across North America's biopharmaceutical sector continues to drive demand for growth factors used in cell culture, drug discovery, and biologics manufacturing. The National Institutes of Health (NIH) has consistently directed multi-billion-dollar annual funding toward biomedical research, supporting academic and commercial laboratories reliant on recombinant growth factors. Additionally, the Biotechnology Innovation Organization (BIO) has highlighted sustained growth in cell and gene therapy pipelines, which depend heavily on high-purity growth factors for cell expansion and differentiation. Companies such as Thermo Fisher Scientific and Bio-Techne Corporation have expanded their recombinant protein portfolios to meet this rising research demand, further strengthening the region's growth factor supply ecosystem.

Restraints - High Cost of Recombinant Growth Factor Production

The production of high-purity recombinant growth factors, particularly those manufactured under Good Manufacturing Practice (GMP) conditions, involves complex bioprocessing and stringent quality control, resulting in significant cost burdens. Regulatory oversight from the U.S. Food and Drug Administration (FDA) mandates rigorous validation and documentation for growth factors used in clinical and therapeutic applications, further increasing compliance costs. These elevated production and regulatory expenses can restrict adoption among smaller research laboratories and academic institutions operating with constrained budgets, potentially limiting broader market penetration despite strong underlying demand for growth factor-based research tools.

Stability and Storage Challenges of Growth Factor Proteins

Growth factor proteins are inherently sensitive to temperature fluctuations, light exposure, and improper handling, which can compromise their biological activity during storage and transport. Maintaining cold-chain logistics across research and clinical supply networks adds operational complexity and cost for manufacturers and distributors alike. Academic institutions and smaller research centers, which may lack advanced cold-storage infrastructure, face a higher risk of product degradation, leading to inconsistent experimental results. This technical limitation continues to pose a restraint on wider adoption of certain growth factor categories, particularly in decentralized or resource-limited laboratory settings across North America.

Opportunities - Rising Demand for Epidermal Growth Factors in Regenerative Medicine

Epidermal Growth Factors (EGFs) are projected to be the fastest-growing product segment between 2026 and 2033, driven by expanding applications in wound healing, dermatology, and regenerative medicine. Rising incidence of diabetic ulcers and chronic wounds, as reported by the American Diabetes Association, has intensified demand for EGF-based topical and injectable therapies that accelerate tissue repair. Companies such as Sino Biological Inc. and GenScript have expanded their EGF product portfolios to support both research and clinical-grade applications.

Additionally, growing interest in cosmetic dermatology and anti-aging treatments is creating new commercial avenues for EGF-based formulations, positioning this segment as a high-potential growth area for manufacturers investing in specialized protein production capabilities.

Growth in Contract Research Organization Outsourcing

The increasing outsourcing of preclinical and clinical research activities to Contract Research Organizations (CROs) presents a substantial opportunity for growth factor suppliers. Pharmaceutical and biotechnology companies are increasingly partnering with CROs to accelerate drug development timelines while managing internal research costs, a trend supported by industry data from the Biotechnology Innovation Organization (BIO). This shift is driving bulk procurement of research-grade and GMP-grade growth factors by CRO laboratories conducting cell-based assays, biomarker studies, and preclinical trials. Companies such as Merck KGaA and Lonza Group AG have strengthened partnerships with CRO networks to supply customized growth factor solutions, positioning suppliers to capture a growing share of outsourced research spending across the region.

Product Analysis

Interleukins held the leading position within the North America growth factors product landscape, accounting for approximately 21% share in 2026. This dominance is attributed to their extensive application in immunology research, cancer immunotherapy, and inflammatory disease studies, areas that continue to attract substantial research funding from institutions such as the National Institutes of Health (NIH). Interleukins play a pivotal role in modulating immune responses, making them indispensable reagents for laboratories studying autoimmune conditions and novel immunotherapy candidates. Leading suppliers, including Cell Signaling Technology, Inc. and Proteintech Group, Inc., have expanded their interleukin portfolios to support growing demand from academic and pharmaceutical research laboratories, reinforcing the segment's sustained leadership across the region's research and clinical pipelines.

Grade Analysis

Non-GMP Grade growth factors led the market, supported by their widespread use across academic research, basic science laboratories, and early-stage drug discovery programs. Non-GMP grade products are generally more cost-effective and readily available in bulk quantities, making them the preferred choice for exploratory research where clinical-grade purity is not required. Research Centers & Academic Institutes, which represent a substantial share of laboratory demand across the United States and Canada, continue to rely heavily on non-GMP reagents for high-throughput experimentation. Suppliers such as Sino Biological Inc. and Proteintech Group, Inc. have expanded their catalog offerings of non-GMP recombinant proteins, ensuring consistent availability for the region's extensive academic and preclinical research ecosystem.

North America Growth Factors Market Trends and Insights

North America represents a mature and research-intensive market for growth factors, underpinned by strong biopharmaceutical infrastructure and substantial government-backed research funding across the United States and Canada. The region's well-established academic research ecosystem, robust regulatory framework overseen by the U.S. Food and Drug Administration (FDA), and growing biologics manufacturing base continue to support consistent demand across both GMP and non-GMP growth factor categories.

U.S. Growth Factors Market Size

The U.S. dominated the North America growth factors market, accounting for approximately 85% of regional revenue in 2025. The country's leadership was supported by extensive NIH-funded biomedical research, a large concentration of pharmaceutical and biotechnology companies, and advanced cell and gene therapy manufacturing capabilities. The NIH received approximately US$47 billion in FY2025, supporting research across oncology, cell biology, regenerative medicine, and advanced therapeutics. Strong clinical development activity and increasing biopharmaceutical investment further sustained demand for recombinant growth factors. These factors supported widespread consumption of both research-grade and clinical-grade growth factors across pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations.

Canada Growth Factors Market Size

Canada accounted for approximately 15% of North America's growth factors market in 2025 and is expected to record strong growth through 2033. Expansion of biotechnology clusters in Ontario and Quebec, combined with increasing investment in biomedical research, is supporting market development. Genome Canada has invested more than C$1.2 billion in genomics research since its establishment, strengthening Canada's life-science research ecosystem. Government and academic initiatives in regenerative medicine, cell therapy, and precision medicine are generating additional demand for recombinant growth factors. Growing collaboration between universities, research institutes, biotechnology companies, and pharmaceutical organizations is expected to further increase adoption of growth factors across research and biopharmaceutical development applications.

The North America growth factors market is moderately consolidated, dominated by established life sciences and biotechnology companies with extensive recombinant protein manufacturing capabilities. Market leaders such as Thermo Fisher Scientific, Merck KGaA, and Bio-Techne Corporation leverage broad product portfolios, global distribution networks, and strong research partnerships to maintain competitive positioning. Companies are increasingly investing in GMP-grade manufacturing expansion, animal-free and recombinant protein technologies, and customized growth factor solutions to differentiate their offerings. Strategic collaborations with contract research organizations and academic institutions, along with continuous portfolio expansion through acquisitions, remain key strategies. Emerging players are also focusing on niche, application-specific growth factor formulations to capture specialized research and clinical demand segments.

Key Developments:

• In June 2026, Merck KGaA agreed to acquire U.S.-based life science tools provider Bio-Techne for approximately US$11.3 billion (€9.9 billion) in an all-cash transaction. Under the agreement, Bio-Techne shareholders were set to receive US$73 per share, representing a 36% premium to the company's one-month volume-weighted average trading price. The acquisition marked Merck KGaA's largest deal in more than a decade and was aimed at strengthening its Life Science business.
• In October 2025, Thermo Fisher Scientific inaugurated an expanded Research and Development Centre of Excellence in Bengaluru, strengthening its capabilities in life sciences and biotechnology innovation. The expansion aimed to enhance advanced research, product development, and engineering functions, while supporting global operations and reinforcing India’s role as a strategic hub for scientific R&D and talent development.
• In January 2025, Bayer UK launched the CanesMeno® educational hub and associated product range, aiming to enhance menopause support for women. The initiative provides information, guidance, and practical solutions to manage menopause symptoms, while introducing new products designed to improve well-being. This move reflects Bayer’s commitment to women’s health and education in the menopause care space.